Patient or Disabled Group – Page 2

Recent Developments in Building Measurable Patient Support Programs (2025)

5 months ago talkbio0Tagged 2025, care activity, collaborative healthcare, Efficiency, Financial cost, measurable outcomes, Medicare reforms, Programs - Publication Format, trends qualifier

patient support programs; measurable outcomes; collaborative healthcare; 2025 trends; Medicare reforms; cost efficiency; access to care

FDA Investigates Patient Deaths Linked to Sarepta’s Elevidys Gene Therapy for Duchenne Muscular Dystrophy

6 months ago talkbio0Tagged ELEVIDYS, Evaluation, gene therapy, Liver, Liver Failure, Acute, Muscular Dystrophy, Duchenne, patient deaths, regulatory, Toxicity aspects, Unable to walk (finding), United States Food and Drug Administration

FDA; Sarepta; Elevidys; Duchenne muscular dystrophy; gene therapy; patient deaths; acute liver failure; liver toxicity; regulatory investigation; non-ambulatory patients

Second Patient Dies After Receiving Sarepta’s Elevidys Gene Therapy for DMD

6 months ago talkbio0Tagged AAV-based gene therapy, ELEVIDYS, gene therapy, Liver Failure, Acute, Muscular Dystrophy, Duchenne, Patient Death, risk mitigation, Unable to walk (finding), United States Food and Drug Administration

Duchenne muscular dystrophy; gene therapy; Sarepta Therapeutics; Elevidys; acute liver failure; AAV-based gene therapy; patient death; non-ambulatory patients; FDA; risk mitigation

Sarepta Halts Duchenne Gene Therapy in Some Patients After Second Death

6 months ago talkbio0Tagged Clinical Trials, ELEVIDYS, gene therapy, Liver Failure, Acute, Muscular Dystrophy, Duchenne, patient safety, Therapeutic immunosuppression, Unable to walk (finding), United States Food and Drug Administration

Sarepta Therapeutics; gene therapy; Duchenne muscular dystrophy; Elevidys; acute liver failure; non-ambulatory patients; FDA; clinical trial pause; immunosuppression; patient safety

Science-Led Storytelling Takes Center Stage in Pharma Communications (June 2025)

6 months ago talkbio0Tagged Cheryl Lubbert, Engaged to be married, Pharma, pharmaceutical communications, Reverba Global, science-led storytelling, Trust (Social Behavior)

pharmaceutical communications; science-led storytelling; pharma marketing; patient engagement; trust and transparency; Cheryl Lubbert; Reverba Global

Where AI Adds Real Value in Clinical Development: 2025 Insights

7 months ago talkbio0Tagged Artificial Intelligence, Clinical Development, Clinical Trials, Data Analysis, Drug Discovery, protocol design, Recruitment, Regulatory Compliance

AI in clinical development; clinical trials; drug discovery; protocol design; patient recruitment; data analysis; regulatory compliance

AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients

7 months ago talkbio0Tagged Clinical Trials, expansion, high-risk, Imfinzi, Malignant neoplasm of urinary bladder

Imfinzi, Clinical Trials, high-risk, expansion, Malignant neoplasm of urinary bladder

Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis

7 months ago talkbio0Tagged Approved, DTC Campaign, Empowerment, Myasthenia Gravis, Generalized, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, self-administration, Syringes, United States Food and Drug Administration, Vyvgart Hytrulo

Vyvgart Hytrulo, prefilled syringe, FDA approval, self-administration, generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), DTC campaign, patient empowerment

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

7 months ago7 months ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

FDA lifts clinical hold on Atara’s Epstein-Barr T-cell programme

7 months ago talkbio0Tagged Atara, Atara 's, Ebvallo, Hoist device, Study on Hold, United States Food and Drug Administration

United States Food and Drug Administration, Study on Hold, Atara, Hoist device, Atara ‘s, EBVALLO